Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cathepsin Z/X: Breaking Down the Known and Unknown.

International journal of molecular sciences·2026

Same author

Transgenerational Transfer and Effects of Polystyrene Nanoplastics in the Floating Macrophyte <i>Spirodela polyrhiza</i>.

Environmental science & technology·2026

Same author

Decoy Nanoparticles and Protein Corona Modulation: A Novel Frontier in Sepsis Treatment.

International journal of nanomedicine·2026

Same author

Biomimetic nanoparticles in cancer photodynamic therapy: a review of targeted delivery systems and therapeutic outcomes.

Beilstein journal of nanotechnology·2026

Same author

From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics.

Asian journal of pharmaceutical sciences·2026

Same author

Route-Specific Phytotoxicity: Foliar Polystyrene Nanoplastics Inhibit Rice Photosynthesis.

Environmental science & technology·2026

Search research articles

Related Experiment Video

Updated: Jul 20, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Smart Delivery Systems Responsive to Cathepsin B Activity for Cancer Treatment.

Vera S Egorova¹, Ekaterina P Kolesova¹, Manu Lopus²

¹Scientific Center for Translation Medicine, Sirius University of Science and Technology, Sochi 354340, Russia.

|July 29, 2023

Summary

Cathepsin B, an enzyme overexpressed in tumors, is a target for novel cancer therapies. Technologies activated by cathepsin B cleavage offer targeted drug delivery and improved cancer treatment strategies.

Keywords:

cathepsin B enzyme-induced cleavage peptide linkers proteolytic activity responsive nanocarrier

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Experiment Videos

Last Updated: Jul 20, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Area of Science:

Biochemistry
Molecular Biology
Oncology

Background:

Cathepsin B is a lysosomal cysteine protease involved in cellular processes like protein turnover and autophagy.
Aberrant overexpression and activity of cathepsin B are linked to various pathologies, notably cancer.
Tumor-associated cathepsin B presents a target for enzyme-responsive drug delivery systems.

Purpose of the Study:

To review technologies designed for cancer treatment that are responsive to cathepsin B activity.
To highlight the role of cathepsin B in cancer progression and treatment response.
To explore the potential of cathepsin B-activated systems for targeted therapy and controlled drug release.

Main Methods:

Literature review of scientific publications and patents.
Analysis of technologies utilizing cathepsin B cleavage for therapeutic activation.
Synthesis of information on cathepsin B's role in cancer and treatment strategies.

Main Results:

Several cathepsin B-responsive technologies have been developed for cancer therapy.
These technologies leverage cathepsin B's overexpression in tumors for targeted drug delivery.
Enzyme-activated systems show promise for controlled drug release and enhanced therapeutic effects.

Conclusions:

Cathepsin B-responsive technologies represent a promising avenue for advanced cancer treatment.
Targeting cathepsin B activity can lead to more effective and localized cancer therapies.
Further development of these smart delivery systems could significantly improve patient outcomes.